Extended criteria donors in liver transplantation Part I: reviewing the impact of determining factors

Expert Review of Gastroenterology and Hepatology

Volumn 10, Issue 7, 2016, Pages 827-839

  Nemes, Balázs ^a   Gámán, György ^b   Polak, Wojciech G ^c   Gelley, Fanni ^d   Hara, Takanobu ^e   Ono, Shinichiro ^e   Baimakhanov, Zhassulan ^e   Piros, Laszlo ^b   Eguchi, Susumu ^e  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Polyclinic of Hospitallers Brothers of St John of God ^*  (Hungary)

^e NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

Author keywords

biliary complications; donor; extended criteria; HCV; hepatitis C; Liver transplantation; machine perfusion; recurrence; steatosis

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS C ANTIBODY; VIRUS RNA;

AGE; ALCOHOL ABUSE; AMINOTRANSFERASE BLOOD LEVEL; COLD ISCHEMIA; EXTENDED CRITERIA DONOR; FATTY LIVER; GOLD STANDARD; GRAFT FAILURE; GRAFT RECIPIENT; HEART DEATH; HEMODYNAMICS; HEPATITIS B; HEPATITIS C; HUMAN; HYPERNATREMIA; HYPOTENSION; LIVER BIOPSY; LIVER FAILURE; LIVER FUNCTION TEST; LIVER GRAFT; LIVER TRANSPLANTATION; ORGAN DONOR; QUALITY CONTROL; RECURRENT INFECTION; REVIEW; RISK FACTOR; TREATMENT CONTRAINDICATION; CAUSE OF DEATH; DONOR; DONOR SELECTION; HEALTH STATUS; HOSPITAL ADMISSION; LIVING DONOR; POSTOPERATIVE COMPLICATION; PREDICTIVE VALUE; PROCEDURES; RISK ASSESSMENT; SUPPLY AND DISTRIBUTION; TIME FACTOR; TREATMENT OUTCOME;

AGE FACTORS; CAUSE OF DEATH; DONOR SELECTION; HEALTH STATUS; HUMANS; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; LIVING DONORS; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TISSUE DONORS; TREATMENT OUTCOME; WAITING LISTS;

EID: 84961203071     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2016.1149061     Document Type: Review

References (104)

1. D.F.Mirza, B.K.Gunson, R.F.Da Silva, et al. Policies in Europe on “marginal quality” donor livers. Lancet. 1994;344(8935):1480–1483.
2. N.R.Barshes, I.B.Horwitz, L.Franzini, et al. Waitlist mortality decreases with increased use of extended criteria donor liver grafts at adult liver transplant centers. Am J Transplant. 2007;7(5):1265–1270.
3. A.Nickkholgh, J.Weitz, J.Encke, et al. Utilization of extended donor criteria in liver transplantation: a comprehensive review of the literature. Nephrol Dial Transplant. 2007;22(Suppl 8):viii29–viii36.
4. P.G.Northup, T.L.Pruett, D.M.Kashmer, et al. Donor factors predicting recipient survival after liver retransplantation: the retransplant donor risk index. Am J Transplant. 2007;7(8):1984–1988.
5. P.Schemmer, A.Nickkholgh, U.Hinz, et al. Extended donor criteria have no negative impact on early outcome after liver transplantation: a single-center multivariate analysis. Transplant Proc. 2007;39(2):529–534.
6. R.C.Afonso, R.Hidalgo, A.T.Paes, et al. Impact of cumulative risk factors for expanded criteria donors on early survival after liver transplantation. Transplant Proc. 2008;40(3):800–801.
7. F.Durand, J.F.Renz, B.Alkofer, et al. Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transpl. 2008;14(12):1694–1707.
8. S.Feng, J.C.Lai Expanded criteria donors. Clin Liver Dis. 2014;18(3):633–649.
9. H.Chen, C.H.Peng, B.Y.Shen, et al. Multi-factor analysis of initial poor graft function after orthotopic liver transplantation. Hepatobiliary Pancreat Dis Int. 2007;6(2):141–146.
10. B.Nemes, F.Gelley, G.Zadori, et al. The role of marginal donors in liver transplantation. The Hungarian experience. Orv Hetil. 2009;150(49):2228–2236.
11. V.Lucidi, A.C.Lemye, L.Baire, et al. Use of marginal donors for liver transplantation: a single-center experience within the Eurotransplant patient-driven allocation system. Transplant Proc. 2007;39(8):2668–2671.
12. G.R.Silberhumer, H.Pokorny, H.Hetz, et al. Combination of extended donor criteria and changes in the model for end-stage liver disease score predict patient survival and primary dysfunction in liver transplantation: a retrospective analysis. Transplantation. 2007;83(5):588–592.
13. B.Mullhaupt, D.Dimitroulis, J.T.Gerlach, et al. Hot topics in liver transplantation: organ allocation–extended criteria donor–living donor liver transplantation. J Hepatol. 2008;48(Suppl 1):S58–67.
14. S.Gordon Burroughs, R.W.Busuttil. Optimal utilization of extended hepatic grafts. Surg Today. 2009;39(9):746–751.
15. G.R.Silberhumer, A.Rahmel, V.Karam, et al. The difficulty in defining extended donor criteria for liver grafts: the Eurotransplant experience. Transpl Int. 2013;26(10):990–998.
16. P.Bruzzone, D.Giannarelli, R.Adam. A preliminary European liver and intestine transplant association-European liver transplant registry study on informed recipient consent and extended criteria liver donation. Transplant Proc. 2013;45(7):2613–2615.
17. T.-J.Wu, C.-F.Lee, H.-S.Chou, et al. Suspect the donor with potential infection in the adult deceased donor liver transplantation. Transplant Proc. 2008;40(8):2486–2488.
18. O.Detry. Extended criteria donors: the case for liver procurement in donors with a central nervous system malignancy. Liver Transpl. 2009;15(6):670–671.
19. O.Nafidi, D.Marleau, A.Roy, et al. Identification of new donor variables associated with graft survival in a single-center liver transplant cohort. Liver Transpl. 2010;16(12):1393–1399.
20. J.C.Hong, H.Yersiz, P.Kositamongkol, et al. Liver transplantation using organ donation after cardiac death: a clinical predictive index for graft failure-free survival. Arch Surg. 2011;146(9):1017–1023.
21. J.J.Blok, A.E.Braat, R.Adam, et al. Validation of the donor risk index in orthotopic liver transplantation within the Eurotransplant region. Liver Transpl. 2012;18(1):112–119.
22. A.Arjona-Sanchez, J.M.Sanchez-Hidalgo, R.Ciria-Bru, et al. Prediction model to discard a priori liver allografts. Transplant Proc. 2014;46(9):3076–3078.
23. J.Zeeh, D.Platt. The aging liver: structural and functional changes and their consequences for drug treatment in old age. Gerontology. 2002;48(3):121–127.
24. B.Nardo, M.Masetti, L.Urbani, et al. Liver transplantation from donors aged 80 years and over: pushing the limit. Am J Transplant. 2004;4(7):1139–1147.
25. M.T.Serrano, A.Garcia-Gil, J.Arenas, et al. Outcome of liver transplantation using donors older than 60 years of age. Clin Transplant. 2010;24(4):543–549.
26. N.R.Fruhauf, C.L.Fischer-Frohlich, M.Kutschmann, et al. Joint impact of donor and recipient parameters on the outcome of liver transplantation in Germany. Transplantation. 2011;92(12):1378–1384.
27. D.Y.Kim, J.Moon, E.R.Island, et al. Liver transplantation using elderly donors: a risk factor analysis. Clin Transplant. 2011;25(2):270–276.
28. R.F.Saidi. Utilization of expanded criteria donors in liver transplantation. Int J Organ Transplant Med. 2013;4(2):46–59.
29. D.Ghinolfi, J.Marti, P.De Simone, et al. Use of octogenarian donors for liver transplantation: a survival analysis. Am J Transplant. 2014;14(9):2062–2071.
30. S.Radunz, A.Paul, K.Nowak, et al. Liver transplantation using donor organs with markedly elevated liver enzymes: how far can we go? Liver Int. 2011;31(7):1021–1027.
31. D.P.Hoyer, A.Paul, F.Saner, et al. Safely expanding the donor pool: brain dead donors with history of temporary cardiac arrest. Liver Int. 2015; 35(6):1756–1763.
32. R.S.Mangus, C.A.Kubal, J.A.Fridell, et al. Alcohol abuse in deceased liver donors: impact on post-transplant outcomes. Liver Int. 2015;35(1):171–175.
33. A.W.Avolio, S.Agnes, S.C.Magalini, et al. Importance of donor blood chemistry data (AST, serum sodium) in predicting liver transplant outcome. Transplant Proc. 1991;23(5):2451–2452.
34. F.X.Gonzalez, A.Rimola, L.Grande, et al. Predictive factors of early postoperative graft function in human liver transplantation. Hepatology. 1994;20(3):565–573.
35. J.Figueras, J.Busquets, L.Grande, et al. The deleterious effect of donor high plasma sodium and extended preservation in liver transplantation. A multivariate analysis. Transplantation. 1996;61(3):410–413.
36. E.Totsuka, U.Fung, K.Hakamada, et al. Analysis of clinical variables of donors and recipients with respect to short-term graft outcome in human liver transplantation. Transplant Proc. 2004;36(8):2215–2218.
37. D.J.Powner. Factors during donor care that may affect liver transplantation outcome. Prog Transplant. 2004;14(3):241–247. quiz 248–249.
38. A.J.Tector, R.S.Mangus, P.Chestovich, et al. Use of extended criteria livers decreases wait time for liver transplantation without adversely impacting posttransplant survival. Ann Surg. 2006;244(3):439–450.
39. E.Totsuka, F.Dodson, A.Urakami, et al. Influence of high donor serum sodium levels on early postoperative graft function in human liver transplantation: effect of correction of donor hypernatremia. Liver Transpl Surg. 1999;5(5):421–428.
40. J.F.Renz, C.Kin, M.Kinkhabwala, et al. Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation. Ann Surg. 2005;242(4):556–563. discussion 563–555.
41. M.Akoad, M.Wagener, F.Francis, et al. Outcome of imported liver allografts and impact on patient access to liver transplantation. Transplant Proc. 2006;38(10):3564–3566.
42. J.B.Cywinski, E.Mascha, C.Miller, et al. Association between donor-recipient serum sodium differences and orthotopic liver transplant graft function. Liver Transpl. 2008;14(1):59–65.
43. R.S.Mangus, J.A.Fridell, R.M.Vianna, et al. Severe hypernatremia in deceased liver donors does not impact early transplant outcome. Transplantation. 2010;90(4):438–443.
44. N.Goldaracena, E.Quinonez, P.Mendez, et al. Extremely marginal liver grafts from deceased donors have outcome similar to ideal grafts. Transplant Proc. 2012;44(7):2219–2222.
45. M.B.Khosravi, M.Firoozifar, S.Ghaffaripour, et al. Early outcomes of liver transplants in patients receiving organs from hypernatremic donors. Exp Clin Transplant. 2013;11(6):537–540.
46. N.Kaseje, S.Luthold, G.Mentha, et al. Donor hypernatremia influences outcomes following pediatric liver transplantation. Eur J Pediatr Surg. 2013;23(1):8–13.
47. M.Uribe, A.Alba, G.Gonzalez, et al. Pediatric liver transplant outcome using severe hypernatremic donors. Transplant Proc. 2013;45(10):3726–3727.
48. R.W.Busuttil, K.Tanaka. The utility of marginal donors in liver transplantation. Liver Transpl. 2003;9(7):651–663.
49. A.Cucchetti, M.Vivarelli, M.Ravaioli, et al. Assessment of donor steatosis in liver transplantation: is it possible without liver biopsy? Clin Transplant. 2009;23(4):519–524.
50. N.Pichon, V.Loustaud-Ratti, M.Clavel, et al. Value of liver stiffness measured by transient elastography in the liver transplant pre-operative evaluation of the potential deceased liver donors: preliminary study. Clin Transplant. 2011;25(2):E205–210.
51. H.Yersiz, C.Lee, F.M.Kaldas, et al. Assessment of hepatic steatosis by transplant surgeon and expert pathologist: a prospective, double-blind evaluation of 201 donor livers. Liver Transpl. 2013;19(4):437–449.
52. A.M.Martins, G.R.Coelho, G.A.Marques, et al. Hepatic steatosis assessment: a comparative study between surgeon evaluation and forward histopathologic findings. Arq Gastroenterol. 2013;50(1):15–18.
53. I.J.Lo, J.H.Lefkowitch, N.Feirt, et al. Utility of liver allograft biopsy obtained at procurement. Liver Transpl. 2008;14(5):639–646.
54. M.Fiorentino, F.Vasuri, M.Ravaioli, et al. Predictive value of frozen-section analysis in the histological assessment of steatosis before liver transplantation. Liver Transpl. 2009;15(12):1821–1825.
55. S.Biesterfeld, J.Knapp, F.Bittinger, et al. Frozen section diagnosis in donor liver biopsies: observer variation of semiquantitative and quantitative steatosis assessment. Virchows Arch. 2012;461(2):177–183.
56. J.B.Oliver, S.Peters, A.Bongu, et al. Prerecovery liver biopsy in the brain-dead donor: a case-control study of logistics, safety, precision, and utility. Liver Transpl. 2014;20(2):237–244.
57. A.M.El-Badry, S.Breitenstein, W.Jochum, et al. Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. Ann Surg. 2009;250(5):691–697.
58. A.L.Spitzer, O.B.Lao, A.A.Dick, et al. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver Transpl. 2010;16(7):874–884.
59. M.K.Angele, M.Rentsch, W.H.Hartl, et al. Effect of graft steatosis on liver function and organ survival after liver transplantation. Am J Surg. 2008;195(2):214–220.
60. J.Briceno, R.Ciria, M.Pleguezuelo, et al. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl. 2009;15(1):37–48.
61. J.F.Botha, E.Thompson, R.Gilroy, et al. Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. Liver Int. 2007;27(6):758–763.
62. P.Burra, M.Loreno, F.P.Russo, et al. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transpl. 2009;15(6):619–628.
63. U.Baccarani, M.Isola, G.L.Adani, et al. Steatosis of the hepatic graft as a risk factor for post-transplant biliary complications. Clin Transplant. 2010;24(5):631–635.
64. B.Lattanzi, Q.Lai, N.Guglielmo, et al. Graft macrosteatosis and time of T-tube removal as risk factors for biliary strictures after liver transplantation. Clin Transplant. 2013;27(3):E332–E338.
65. V.Subramanian, A.B.Seetharam, N.Vachharajani, et al. Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation. Transplantation. 2011;92(11):1259–1268.
66. R.Adam, V.Cailliez, P.Majno, et al. Normalised intrinsic mortality risk in liver transplantation: European liver transplant registry study. Lancet. 2000;356(9230):621–627.
67. A.K.Burroughs, C.A.Sabin, K.Rolles, et al. 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet. 2006;367(9506):225–232.
68. European Liver Transplant Registry. [cited 2008 Sep]. Available from: http://www.eltr.org
69. R.Ballarin, A.Cucchetti, M.Spaggiari, et al. Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study. Transplantation. 2011;91(11):1265–1272.
70. M.Berenguer. Risk of extended criteria donors in hepatitis C virus-positive recipients. Liver Transpl. 2008;14(Suppl 2):S45–50.
71. A.T.Burr, Y.Li, J.F.Tseng, et al. Survival after liver transplantation using hepatitis C virus-positive donor allografts: case-controlled analysis of the UNOS database. World J Surg. 2011;35(7):1590–1595.
72. P.G.Northup, C.K.Argo, D.T.Nguyen, et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int. 2010;23(10):1038–1044.
73. J.G.O’Leary, M.A.Neri, J.F.Trotter, et al. Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined. Transpl Int. 2012;25(8):825–829.
74. E.Cholongitas, G.V.Papatheodoridis, A.K.Burroughs. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol. 2010;52(2):272–279.
75. M.Prieto. Antibody to hepatitis B core antigen-positive grafts: not perfect but no longer marginal. Liver Transpl. 2009;15(10):1164–1168.
76. E.Loggi, F.Bihl, J.V.Chisholm3rd, et al. Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft. J Hepatol. 2009;50(3):625–630.
77. L.Yu, T.Koepsell, L.Manhart, et al. Survival after orthotopic liver transplantation: the impact of antibody against hepatitis B core antigen in the donor. Liver Transpl. 2009;15(10):1343–1350.
78. M.Angelico, A.Nardi, T.Marianelli, et al. Hepatitis B-core antibody positive donors in liver transplantation and their impact on graft survival: evidence from the liver match cohort study. J Hepatol. 2013;58(4):715–723.
79. M.P.MacConmara, N.Vachharajani, J.R.Wellen, et al. Utilization of hepatitis B core antibody-positive donor liver grafts. HPB (Oxford). 2012;14(1):42–48.
80. G.N.Brock, F.Mostajabi, N.Ferguson, et al. Prophylaxis against de novo hepatitis B for liver transplantation utilizing hep B core (+) donors: does hepatitis B immunoglobulin provide a survival advantage? Transpl Int. 2011;24(6):570–581.
81. C.L.Skagen, J.H.Jou, A.Said. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts - a systematic analysis. Clin Transplant. 2011;25(3):E243–249.
82. R.Y.Calne, R.Williams. Liver transplantation in man. I: observations on technique and organization in five cases. Br Med J. 1968;4(5630):535–540.
83. R.H.Broomhead, S.Patel, B.Fernando, et al. Resource implications of expanding the use of donation after circulatory determination of death in liver transplantation. Liver Transpl. 2012;18(7):771–778.
84. M.Wells, K.M.Croome, T.Janik, et al. Comparing outcomes of donation after cardiac death versus donation after brain death in liver transplant recipients with hepatitis C: a systematic review and meta-analysis. Can J Gastroenterol Hepatol. 2014;28(2):103–108.
85. J.H.Nguyen, H.Bonatti, R.C.Dickson, et al. Long-term outcomes of donation after cardiac death liver allografts from a single center. Clin Transplant. 2009;23(2):168–173.
86. A.I.Skaro, C.L.Jay, T.B.Baker, et al. The impact of ischemic cholangiopathy in liver transplantation using donors after cardiac death: the untold story. Surgery. 2009;146(4):543–552. discussion 552–543.
87. A.K.Mathur, J.Heimbach, D.E.Steffick, et al. Donation after cardiac death liver transplantation: predictors of outcome. Am J Transplant. 2010;10(11):2512–2519.
88. A.Abou Abbass, M.Abouljoud, A.Yoshida, et al. Biliary complications after orthotopic liver transplantation from donors after cardiac death: broad spectrum of disease. Transplant Proc. 2010;42(9):3392–3398.
89. A.Bartlett, R.Vara, P.Muiesan, et al. A single center experience of donation after cardiac death liver transplantation in pediatric recipients. Pediatr Transplant. 2010;14(3):388–392.
90. G.Yagci, L.A.Fernandez, S.J.Knechtle, et al. The impact of donor variables on the outcome of orthotopic liver transplantation for hepatitis C. Transplant Proc. 2008;40(1):219–223.
91. R.Tao, K.Ruppert, R.J.CruzJr., et al. Hepatitis C recurrence is not adversely affected by the use of donation after cardiac death liver allografts. Liver Transpl. 2010;16(11):1288–1295.
92. M.Mawardi, F.Aba Alkhail, K.Katada, et al. The clinical consequences of utilizing donation after cardiac death liver grafts into hepatitis C recipients. Hepatol Int. 2011;5(3):830–833.
93. R.Hernandez-Alejandro, K.P.Croome, D.Quan, et al. Increased risk of severe recurrence of hepatitis C virus in liver transplant recipients of donation after cardiac death allografts. Transplantation. 2011;92(6):686–689.
94. C.B.Taner, I.G.Bulatao, A.P.Keaveny, et al. Use of liver grafts from donation after cardiac death donors for recipients with hepatitis C virus. Liver Transpl. 2011;17(6):641–649.
95. T.Uemura, V.Ramprasad, C.S.Hollenbeak, et al. Liver transplantation for hepatitis C from donation after cardiac death donors: an analysis of OPTN/UNOS data. Am J Transplant. 2012;12(4):984–991.
96. L.Tariciotti, C.Rocha, M.T.Perera, et al. Is it time to extend liver acceptance criteria for controlled donors after cardiac death? Transplantation. 2011;92(10):1140–1146.
97. D.Monbaliu, J.Pirenne, D.Talbot. Liver transplantation using donation after cardiac death donors. J Hepatol. 2012;56(2):474–485.
98. C.Fondevila, A.J.Hessheimer, E.Flores, et al. Applicability and results of maastricht type 2 donation after cardiac death liver transplantation. Am J Transplant. 2012;12(1):162–170.
99. T.R.Harring, N.T.Nguyen, R.T.Cotton, et al. Liver transplantation with donation after cardiac death donors: a comprehensive update. J Surg Res. 2012;178(1):502–511.
100. C.L.Jay, A.I.Skaro, D.P.Ladner, et al. Comparative effectiveness of donation after cardiac death versus donation after brain death liver transplantation: recognizing who can benefit. Liver Transpl. 2012;18(6):630–640.
101. L.Mccormack, H.Petrowsky, W.Jochum, et al. Use of severely steatotic grafts in liver transplantation: a matched case-control study. Ann Surg. 2007;246(6):940–948. discussion 946–948.
102. P.Dutkowski, A.Schlegel, K.Slankamenac, et al. The use of fatty liver grafts in modern allocation systems: risk assessment by the balance of risk (BAR) score. Ann Surg. 2012;256(5):861–869. discussion 868–869.
103. J.R.Scalea, R.N.Barth, R.Munivenkatappa, et al. Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts. Transplantation. 2015;99(6):1192–1196.
104. O.Aubert, N.Kamar, D.Vernerey, et al. Long term outcomes of transplantation using kidneys from expanded criteria donors: prospective, population based cohort study. BMJ. 2015;351:h3557. doi:10.1136/bmj.h3557